Emerging antibody-drug conjugates for treating lymphoid malignancies

Anna Wolska-Washer1, Pawel Robak2, Piotr Smolewski2

  • 1a Department of Hematology , Medical University of Lodz , Lodz , Poland.

Summary

Antibody-drug conjugates (ADCs) show promise for treating blood cancers like lymphoma and leukemia by targeting cancer cells. Further clinical trials are needed to confirm their effectiveness and optimal use.

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
18.0K
Antibody Actions01:26

Antibody Actions

Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
3.1K